...
首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >The Maximal Pore Size of Hydrophobic Microporous Membranes Does Not Fully Characterize the Resistance to Plasma Breakthrough of Membrane Devices for Extracorporeal Blood Oxygenation
【24h】

The Maximal Pore Size of Hydrophobic Microporous Membranes Does Not Fully Characterize the Resistance to Plasma Breakthrough of Membrane Devices for Extracorporeal Blood Oxygenation

机译:疏水性微孔膜的最大孔径并未完全表征膜装置的膜装置抗血浆突破,用于体外血氧氧合

获取原文
           

摘要

hydrophobic membranes has become routine treatment of respiratory or cardiac failure. In spite of membrane hydrophobicity, significant amounts of plasma water may form in the gas compartment during treatment, an event termed plasma water breakthrough. When this occurs, plasma water occludes some gas pathways and ultimately cripples the oxygenator gas exchange capacity requiring its substitution. This causes patient hemodilution and increases the activation of the patient’s immune system. On these grounds, the resistance to plasma water breakthrough is regarded as an important feature of ECMO devices. Many possible events may explain the occurrence of plasma breakthrough. In spite of this, the resistance to plasma breakthrough of ECMO devices is commercially characterized only with respect to the membrane maximal pore size, evaluated by the bubble pressure method or by SEM analysis of membrane surfaces. The discrepancy between the complexity of the events causing plasma breakthrough in ECMO devices (hence determining their resistance to plasma breakthrough), and that claimed commercially has caused legal suits on the occasion of the purchase of large stocks of ECMO devices by large hospitals or regional institutions. The main aim of this study was to identify some factors that contribute to determining the resistance to plasma breakthrough of ECMO devices, as a means to minimize litigations triggered by an improper definition of the requirements of a clinically efficient ECMO device. The results obtained show that: membrane resistance to breakthrough should be related to the size of the pores inside the membrane wall rather than at its surface; membranes with similar nominal maximal pore size may exhibit pores with significantly different size distribution; membrane pore size distribution rather than the maximal pore size determines membrane resistance to breakthrough; the presence of surfactants in the patient’s blood (e.g. lipids, alcohol, etc.) may significantly modify the intrinsic membrane resistance to breakthrough, more so the higher the surfactant concentration. We conclude that the requirements of ECMO devices in terms of resistance to plasma breakthrough ought to account for all these factors and not rely only on membrane maximal pore size.
机译:疏水性膜已成为呼吸或心脏衰竭的常规治疗。尽管存在膜疏水性,但在治疗过程中可以在气体室中形成大量的等离子体水,但是血浆水分突破的事件。当发生这种情况时,等离子体水遮挡了一些气体途径,最终捕获了需要替代的氧气器气体交换能力。这会导致患者的血液稀释,并增加患者免疫系统的激活。在这些场地上,对等离子体水突破的抗性被认为是ECMO器件的重要特征。许多可能的事件可以解释等离子体突破的发生。尽管如此,ECMO器件的抗血浆突破仅是通过气泡压力法评估的膜最大孔径的商业特征,或者通过对膜表面的SEM分析评估。导致ECMO器件中导致等离子体突破的事件的复杂性之间的差异(因此确定它们对等离子体突破的抵抗),并声称商业上造成了大型医院或区域机构购买大型ECMO设备的法律诉讼。本研究的主要目的是确定有助于确定对ECMO器件的抗血浆突破性的抗性的一些因素,作为最小化因临床有效的ECMO装置要求的不当定义引发的诉讼的方法。得到的结果表明:对突破的膜抗性应与膜壁内的孔的尺寸有关而不是其表面​​;具有相似标称最大孔径的膜可表现出具有明显不同尺寸分布的孔隙;膜孔径分布而不是最大孔径决定膜抗突破;患者血液中的表面活性剂(例如脂质,醇等)可以显着改变对突破的内在膜抗性,更高的表面活性剂浓度越高。我们得出结论,ECMO器件在对等离子体突破的抵抗方面的要求应该考虑所有这些因素,并且不仅仅依赖于膜最大孔径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号